Literature DB >> 7563597

[Secondary myeloid/natural killer cell acute leukemia appeared in multiple myeloma treated with melphalan].

H Kaya1, S Nakamura, H Yamazaki, I Kumabashiri, S Ohtake, T Matsuda.   

Abstract

A 67-year-old woman was treated with MP-P therapy and combination chemotherapy for multiple myeloma IgG-lambda type. After the therapy for about three years, pancytopenia developed. Bone marrow aspiration study revealed a few of myeloma cell and many atypical cells showing promyelocytic feature. Chromosomal abnormality was 46, X, -X, +8, -13, +mar. CD33 and CD56 were positive, but CD16 and HLA-DR were negative. We diagnosed as multiple myeloma complicated with secondary myeloid/natural killer (NK) cell acute leukemia. After she had been treated with low dose etoposide for leukemia, she obtained complete remission. But since myeloma progressed and the amount of M protein was increased, she was treated with dexamethasone and low dose etoposide, resulting in a decrease in the amount of M protein. After that, because of leukemic cell re-proliferation, she was treated with etoposide. However, she died of sepsis due to severe myelosuppression. This case was interesting one in coexist of multiple myeloma and secondary myeloid/NK cell acute leukemia, and those affecting her clinical course each other.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7563597

Source DB:  PubMed          Journal:  Rinsho Ketsueki        ISSN: 0485-1439


  2 in total

1.  Diagnostic challenges related to myeloid/natural killer cells, a variant of myeloblasts.

Authors:  Guilin Tang; Franciose Truong; Oluwole Fadare; Bruce Woda; Sa A Wang
Journal:  Int J Clin Exp Pathol       Date:  2008-01-28

Review 2.  Apigenin role as cell-signaling pathways modulator: implications in cancer prevention and treatment.

Authors:  Zeeshan Javed; Haleema Sadia; Muhammad Javed Iqbal; Shazia Shamas; Kausar Malik; Rais Ahmed; Shahid Raza; Monica Butnariu; Natalia Cruz-Martins; Javad Sharifi-Rad
Journal:  Cancer Cell Int       Date:  2021-04-01       Impact factor: 5.722

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.